Vertex Pharmaceuticals Stock News

Vertex Pharmaceuticals Incorporated remains a leader in cystic fibrosis treatments, fueling robust cash flow and funding a promising pipeline expansion. VRTX is seeing early but accelerating revenue from new products Casgevy and Journavx, with non-CF revenue projected to reach 16-20% by 2032. The VRTX pipeline includes potential blockbusters in kidney disease, with key FDA decisions expected in...

Novo Nordisk's business is well-equipped to rebound in the GLP-1 market. Vertex is set to launch a couple of new medicines in the next few years.

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in the UBS Global Healthcare Conference. Reshma Kewalramani, President and Chief Executive Officer will participate in a fireside chat on Tuesday, November 11, 2025, at 10:15 a.m. ET. A live webcast of management's remarks will be available through the Vertex website, www.vrtx.co...

Pfizer is racing towards patent cliffs that will lead to even worse financial results. Vertex Pharmaceuticals is posting strong revenue growth and excellent clinical progress.

Google parent Alphabet is well-positioned to win in the AI, cloud, robotaxi, and quantum computing markets. Dominion Energy is a backdoor AI play with a stable business and juicy dividend.

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the presentation of multiple abstracts demonstrating the clinical benefits of treatment with CFTR modulators, including the Company's most recently approved medicine, ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor), at the North American Cystic Fibrosis Conference (NACFC) held from October 22-25 in Seat...

Some growth stocks on the market are grabbing much of the attention and seeing their share prices soar, perhaps thanks to their work in an exciting field like artificial intelligence. Others haven't had that kind of luck this year.

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in Ig...